Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance

This study evaluates an individualized approach combining highly active maintenance treatment with elranatamab with peripheral blood-based clonotypic measurable residual disease (MRD) testing in patients with newly diagnosed multiple myeloma. The overall goal is to generate efficacy data for a personalized maintenance approach using bone marrow-based MRD testing (clonoSEQ) to guide post-autologous hematopoietic cell transplant (AHCT) maintenance with elranatamab for this patient population.

NCT Number	NCT06483100
Lead Sponsor	Washington University School of Medicine Collaborators: National Comprehensive Cancer Network, Pfizer
Conditions	Multiple Myeloma
Enrollment	65 participants
Start Date	2024-12-20
Primary Completion	2031-12-31 (estimated)
Study Completion	2031-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-04-13